Key result
Intravenous iloprost linked to ~31% lower total peripheral resistance alongside increased cardiac index.
Why the study?
What are the hemodynamic effects of intravenous iloprost in patients with advanced obliterative arterial disease?
What are the hemodynamic effects of intravenous iloprost in patients with advanced obliterative arterial disease?
Intravenous iloprost acts as a potent vasodilator that reduces pre- and afterload and increases cardiac output without increasing the work load or oxygen demand of the heart.
Answers are grounded in this paper and cite their sources.
Case report data should not change practice; leaves open iloprost's hemodynamic role in advanced obliterative arterial disease.
Iloprost is a chemically stable derivative of carbaprostacyclin. We studied its hemodynamic effects in 10 patients in an intensive care unit. Iloprost was infused intravenously for 3 days for the treatment of advanced obliterative arterial disease of the lower extremities. Clinically significant hemodynamic responses were obtained with an infusion rate of 0.5 ng/kg/min. All subjects tolerated the dose of 4 ng/kg/min, which increased heart rate an average of 11% and cardiac index an average of 26%. This infusion rate decreased mean arterial pressure by 15%, total peripheral resistance by 31%, and pulmonary vascular resistance by 34%. Mean pulmonary arterial pressure, pulmonary capillary wedge pressure, left and right ventricular stroke work indices, and rate pressure product did not change. At higher doses of up to 8 ng/kg/min, responses were augmented only slightly, but side effects such as headache, nausea, and abdominal colics became more prominent. The data show iloprost to be a potent vasodilator that reduces both pre- and afterload and presumably induces a compensatory increase in cardiac output and heart rate, but does not increase the work load or oxygen demand of the heart.
No takes yet. Share an insight, caveat, or question.
Kaukinen et al. (1984) studied Advanced obliterative arterial disease of the lower extremities (n=10). Iloprost was evaluated on Hemodynamic responses (including heart rate, cardiac index, mean arterial pressure, and vascular resistance). Intravenous iloprost at 4 ng/kg/min increased heart rate by 11% and cardiac index by 26%, while decreasing mean arterial pressure by 15% and total peripheral resistance by 31%.
Synapse has enriched 10 related papers. Consider them for comparative context: